A 3 Month, Randomized, Open Label, Multi-center Study of Technosphere/Insulin Compared to Insulin Aspart in Subjects With Type 1 Diabetes Mellitus Receiving Insulin Glargine

NCT00539396 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 1

Interventions

DRUG: Technosphere Insulin

Sponsor

Mannkind Corporation